Advanced Biomed Inc. 8-K

What Happened

• Advanced Biomed Inc. announced it completed the acquisition of Acellent Technologies (Hong Kong) Co. Limited (the “Target”) and issued 270,000 shares of its common stock (valued at $4.00/share, aggregate $1,080,000) as purchase consideration. The acquisition closed on April 30, 2026 and the shares were issued in reliance on Section 4(a)(2) of the Securities Act.
• The company also announced a strategic pivot from life sciences to artificial intelligence development. As part of that transition, Yi Lu and the Company mutually agreed to a leadership transition; Mr. Lu was separated from his roles as CEO, director and Chairman and received 39,999 shares of common stock as severance under a Termination Agreement dated April 28, 2026.
• The Board appointed Xiaomin Chen as Chief Executive Officer, director and Chairman of the Board effective April 28, 2026. Mr. Chen is the former CEO of Acellent (the acquired company) with over 20 years of AI and fintech experience and holds a Ph.D. in Computer Science from Rutgers University.

Key Details

• Acquisition consideration: 270,000 common shares at $4.00 per share = $1,080,000 (issued April 30, 2026).
• Severance to former CEO Yi Lu: 39,999 common shares pursuant to a Termination Agreement dated April 28, 2026.
• Leadership change effective: April 28, 2026 — Xiaomin Chen appointed CEO, director and Chairman.
• Transaction structure: Shares issued in reliance on Section 4(a)(2) (unregistered sale exemption).

Why It Matters

• Business direction: The company’s announced Strategic Pivot from life sciences to artificial intelligence is a material shift in strategy that could change its product focus, markets, and risk profile — investors should note the company is repositioning into AI and fintech-related offerings.
• Leadership and integration: The new CEO, Xiaomin Chen, led the acquired company and brings direct AI/FinTech expertise; his appointment aligns leadership with the new strategy and may accelerate integration of Acellent’s AI assets.
• Equity impact: The company issued a total of 309,999 shares in connection with these actions (270,000 for the acquisition and 39,999 as severance). Investors should monitor disclosures for any further details on share counts, dilution, financing, or material financial impacts in future filings.

Exhibits referenced in the filing include the Termination Agreement and Employment Agreement dated April 28, 2026.